John Ryan: A Living Miracle
When the Johns Hopkins Cancer Unit rolled out its next‑gen immunotherapy, they hadn’t expected the result to be a 74‑year‑old retired military nuclear specialist still blowing out his birthday candles in July. But that’s exactly what happened—because chemotherapy’s been so brutal, the only hope left was Nivolumab (brand name Opdivo).
Ryan’s Road to Recovery
- 2013: Chemo drives him into a 18‑month “I can’t wait to pass” scenario.
- Late 2013: Joined a last‑ditch clinical trial—Opdivo infused every two weeks, then monthly.
- Spurting the tumor away: 104 injections later, the biggest side effect was a sneaky itch.
- 2023: Found and treated a mysterious lung mass with radiation.
“They shot me with chemo, it almost killed me. And now I’ve been chewing on immunotherapy, and it’s been good. My quality of life has been great,” Ryan shares with a bright smile.
The Power of Immunotherapy
Unlike chemotherapy’s ‘kill‑both‑sides’ approach—destroying tumor cells but stealing healthy ones—immunotherapy gets the body’s own guardians, the T‑cells, to spot and snap up cancer. That’s why it can give a minority of patients a real chance at long‑term remission.
Why It Works (and Why It Doesn’t)
- Success stories: Roughly 10‑15% of patients experience remission lasting years, not just a year or two.
- Limitations: Not all cancers trigger a strong immune response; brain tumors, for instance, are still the oddballs that resist these tricks.
- The sweet spot: Leukemia, breast, lung, cervical, colorectal, and melanoma are front‑liners in the immunotherapy revolution.
Beyond the Old Ways: Chemo & Radiation
It’s hard to forget the battlefield of chemo and radiation—tough, toxic, but often unavoidable. Still, the latest clinical trials are proving that some cancers can be tackled with slicker, less scar‑ticking methods. One example? A recent study revealing that many women didn’t need chemo at all after breast cancer surgery and hormones—turns out the industry was over‑cautious.
Personalized Treatments: The Finishing Touch
Genetic profiling of tumors is the new GPS for cancer medication, letting doctors tailor therapy to a tumor’s specific DNA blueprint. Johns Hopkins now runs a genomic lab that keeps track of thousands of tumor genes, enabling the “yes, you need it; no, you don’t” approach.
Ryan’s Vision: A Future Where Metastatic Cancer is Manageable
Oncologist Julie Brahmer hopes day arrives when metastatic cancers—those that spread like a bad rumor—become chronic conditions rather than death sentences. To Ryan, that translates into a straightforward goal: “I want to die of something other than lung cancer.”
The Bottom Line
- Immunotherapy shows promise for a select group of patients.
- Chemo and radiation remain the default weapons, but we’re chasing new ammo.
- Personalized treatment is the growing tide that’s making oncologists’ job easier and patients’ lives longer.
